Copy to clipboard 
Below we’ve selected comments from the leaders of top orthopedic companies as they reported 4Q earnings. In this installment, we focus on their thoughts about M&A, enabling technology and overall commercial strategy.
Transitioning from Integration to Execution
Ivan Tornos, Zimmer Biomet CEO
Recall that we’ve done three acquisitions between OrthoGrid, Paragon 28 and then, a few months after that, Monogram. These are pretty significant projects. And then add on top of that this transformation of the U.S. channel. This is not the time to add more complexity. This is not the time to run more projects.
Damien McDonald, Enovis CEO
We’ve transformed and reshaped our portfolio in a short amount of time, and 2025 was a pivotal year in moving from integration to execution.
Keith Pfeil, Globus Medical CEO
We are moving past the M&A digestion of the past several years and see a path to meaningful and expanded product development investment, continued above-market sales growth and sustainable operating leverage.
Enabling Tech Share Battle Heating Up
Geoffrey Martha, Medtronic CEO
We’ve got a number of businesses here that are going to start growing faster than they have been recently. One is CST with the Stealth AXiS. I think this is underappreciated, quite frankly, by the Street. This is not just a new robot. It’s not just an extension of Mazor; it’s a whole new platform that has a lot of benefits to it, and I think that’s going to create growth for the short and long term for CST.
Pat Miles, ATEC CEO
PTP Valence is a fully integrated platform that provides both navigation and robotically controlled precision where required. It is part of the design workflow of surgery. It’s not anything other than part of the surgery as we have designed it. We are very excited for a controlled release throughout ’26 and as the replacement cycle for Stealth avails itself, we will happily assert ourselves.
Jason Beach, Stryker VP of Finance and IR
Powered by Mako 4, we delivered a stunning quarter and year of Mako installations with yet another record quarter, both in the U.S. and worldwide. Our installed base now includes more than 3,000 Mako systems worldwide.
Leaders Talk Strategy for 2026 and Beyond
Kevin Lobo, Stryker CEO
I really want to make sure we are an AI forward company. We’ve done a terrific job on AI for customer solutions, but we really haven’t made a lot of progress yet on productivity with AI. We’ve done a great job on lean and a much better job on inventory, but there’s a lot of work we can do to drive productivity in AI.
Pat Miles, ATEC CEO
The reason surgeons adopt is that when we see a prospective operative candidate, a patient, they don’t think widgets; they think, what spine procedure can I apply to help this patient? They want a fully thought out contemplation of how to address specific pathology. When they experience that, it creates trust. That trust creates confidence or a halo into earning more of their practice. This is how utilization increased, more surgical success creates more confidence and more users. More confidence creates more utilization.
Mike Cordonnier, Carlsmed CEO
At Carlsmed, we aim to improve spine surgery through our preoperative, intraoperative and postoperative aprevo digital surgery platform. We create AI-driven personalized surgical plans and 3D-printed custom-made anatomically designed spine fusion systems. Unlike traditional one-size-fits-all approaches, real-world evidence suggests that our aprevo platform solution has the potential to improve outcomes and reduce the number of revision surgeries. We are fundamentally changing how spine surgery is planned and executed and how patients are treated.
Below we've selected comments from the leaders of top orthopedic companies as they reported 4Q earnings. In this installment, we focus on their thoughts about M&A, enabling technology and overall commercial strategy.
Transitioning from Integration to Execution
Ivan Tornos, Zimmer Biomet CEO
Recall that we've done three...
Below we’ve selected comments from the leaders of top orthopedic companies as they reported 4Q earnings. In this installment, we focus on their thoughts about M&A, enabling technology and overall commercial strategy.
Transitioning from Integration to Execution
Ivan Tornos, Zimmer Biomet CEO
Recall that we’ve done three acquisitions between OrthoGrid, Paragon 28 and then, a few months after that, Monogram. These are pretty significant projects. And then add on top of that this transformation of the U.S. channel. This is not the time to add more complexity. This is not the time to run more projects.
Damien McDonald, Enovis CEO
We’ve transformed and reshaped our portfolio in a short amount of time, and 2025 was a pivotal year in moving from integration to execution.
Keith Pfeil, Globus Medical CEO
We are moving past the M&A digestion of the past several years and see a path to meaningful and expanded product development investment, continued above-market sales growth and sustainable operating leverage.
Enabling Tech Share Battle Heating Up
Geoffrey Martha, Medtronic CEO
We’ve got a number of businesses here that are going to start growing faster than they have been recently. One is CST with the Stealth AXiS. I think this is underappreciated, quite frankly, by the Street. This is not just a new robot. It’s not just an extension of Mazor; it’s a whole new platform that has a lot of benefits to it, and I think that’s going to create growth for the short and long term for CST.
Pat Miles, ATEC CEO
PTP Valence is a fully integrated platform that provides both navigation and robotically controlled precision where required. It is part of the design workflow of surgery. It’s not anything other than part of the surgery as we have designed it. We are very excited for a controlled release throughout ’26 and as the replacement cycle for Stealth avails itself, we will happily assert ourselves.
Jason Beach, Stryker VP of Finance and IR
Powered by Mako 4, we delivered a stunning quarter and year of Mako installations with yet another record quarter, both in the U.S. and worldwide. Our installed base now includes more than 3,000 Mako systems worldwide.
Leaders Talk Strategy for 2026 and Beyond
Kevin Lobo, Stryker CEO
I really want to make sure we are an AI forward company. We’ve done a terrific job on AI for customer solutions, but we really haven’t made a lot of progress yet on productivity with AI. We’ve done a great job on lean and a much better job on inventory, but there’s a lot of work we can do to drive productivity in AI.
Pat Miles, ATEC CEO
The reason surgeons adopt is that when we see a prospective operative candidate, a patient, they don’t think widgets; they think, what spine procedure can I apply to help this patient? They want a fully thought out contemplation of how to address specific pathology. When they experience that, it creates trust. That trust creates confidence or a halo into earning more of their practice. This is how utilization increased, more surgical success creates more confidence and more users. More confidence creates more utilization.
Mike Cordonnier, Carlsmed CEO
At Carlsmed, we aim to improve spine surgery through our preoperative, intraoperative and postoperative aprevo digital surgery platform. We create AI-driven personalized surgical plans and 3D-printed custom-made anatomically designed spine fusion systems. Unlike traditional one-size-fits-all approaches, real-world evidence suggests that our aprevo platform solution has the potential to improve outcomes and reduce the number of revision surgeries. We are fundamentally changing how spine surgery is planned and executed and how patients are treated.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
